Satoru Koyano
Project Team for Pharmacogenetics, National Institute of Health Sciences, Setagaya-ku, Tokyo 158-8501, Japan
Yoshiro Saito
Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, Setagaya-ku, Tokyo 158-8501, Japan
Shogo Ozawa
Project Team for Pharmacogenetics, National Institute of Health Sciences, Setagaya-ku, Tokyo 158-8501, Japan
Atsuko Miyajima
Project Team for Pharmacogenetics, National Institute of Health Sciences, Setagaya-ku, Tokyo 158-8501, Japan
Jun -ichi Sawada
Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, Setagaya-ku, Tokyo 158-8501, Japan
ABSTRACT
Glucocorticoids are widely used as potent anti-inflammatory drugs. Glucocorticoids exert their pharmacological effects by binding to glucocorticoid receptor (GR), which promotes expression of its target genes, or suppresses transcription mediated by other transcriptional factors, such as nuclear factor-κB (NF-κB). We had recently found one novel single nucleotide polymorphism, 420G>T (K140N), in the glucocorticoid receptor gene in Japanese subjects. In transiently transfected COS-7 cells, the expression of the K140N variant protein was approximately 14% of the wild type protein, although their mRNA levels were almost equivalent. When the transfected COS-7 cells were treated with a proteasome inhibitor MG-132, the K140N variant protein levels were increased 3-fold whereas those of the wild type were increased by 1.5-fold. Immunocytochemistry revealed that the K140N variant protein was localized similar to the wild type protein. The luciferase reporter assay in COS-7 cells treated with 100 nM dexamethasone showed that the overall luciferase activity of the K140N variant was reduced to approximately 67% of the wild type. Thus, the K140N variation was suggested to influence the response to glucocorticoid treatment.
PDF References
How to cite this article
Satoru Koyano, Yoshiro Saito, Shogo Ozawa, Atsuko Miyajima and Jun -ichi Sawada, 2005. Functional Characterization of a K140N Human Glucocorticoid Receptor Variant. International Journal of Pharmacology, 1: 316-323.
DOI: 10.3923/ijp.2005.316.323
URL: https://scialert.net/abstract/?doi=ijp.2005.316.323
DOI: 10.3923/ijp.2005.316.323
URL: https://scialert.net/abstract/?doi=ijp.2005.316.323
REFERENCES
- Savory, J.G., B. Hsu, I.R. Laquian, W. Giffin, T. Reich, R.J. Hache and Y.A. Lefebvre, 1999. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol. Cellular Biol., 19: 1025-1037.
Direct Link - Pratt, W.B. and D.O. Toft, 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Rev., 18: 306-360.
CrossRefDirect Link - Kino, T., R.H. Stauber, J.H. Resau, G.N. Pavlakis and G.P. Chrousos, 2002. Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: Importance of the ligand-binding domain for intracellular GR trafficking. J. Clin. Endocrinol. Metab., 86: 5600-5608.
- Sanchez, E.R., P.R. Housley and W.B. Pratt, 1986. The molybdate-stabilized glucocorticoid binding complex of L-cells contains a 98-100 kdalton steroid binding phosphoprotein and a 90 kdalton nonsteroid-binding phosphoprotein that is part of the murine heat-shock complex. J. Steroid Biochem., 24: 9-18.
- Iniguez-Lluhi, J.A. and D. Pearce, 2000. A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Mol. Cellular Biol., 20: 6040-6050.
Direct Link